Literature DB >> 17804207

Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST).

Gian Marco Leggio1, Vincenzo Micale, Filippo Drago.   

Abstract

Evidence exists for a dopaminergic system dysregulation in mood disorders. In particular, depression may be accompanied by a relative fall of brain dopamine (DA) availability, while the increase of dopamine D2/D3 receptors (D2R/D3R) binding may reflect a compensatory change following primary reduction of mesolimbic DA levels. It is well established that D3Rs, acting as autoreceptors, inhibit DA synthesis and release, although lack of selective compounds have limited the progress in understanding D3Rs role in mood disorders. Aim of this study was to assess the behavioral responses of D3R-deficient (D3(-/-)) mice tested in the forced swim test (FST) and to evaluate their sensitivity to the treatment with different antidepressant drugs. Different groups of mice received one injection of the tricyclic compound, clomipramine (1, 5 and 10 mg/kg) or of one the selective serotonin reuptake inhibitors (SSRIs), paroxetine, sertraline or citalopram (1, 4 and 16 mg/kg), 30 min prior the behavioral test. Vehicle-injected wild type (WT) mice and D3(-/-) animals were used as controls and submitted to the same experimental procedure. In a preliminary experiment, vehicle-injected D3(-/-) mice, but not their littermates, failed to show an increased immobility time in FST as compared to intact controls, suggesting an increased resistance to injection-induced stress in the former. Clomipramine 1 mg/kg failed to affect behavioral responses of both D3(-/-) mice and WT animals. After the 5 mg/kg dose, D3(-/-) and WT mice showed a better performance in FST than vehicle-injected controls, with a lower immobility time exhibited by D3(-/-) mice than that shown by WT animals. No difference was found between WT mice treated with the highest dose of clomipramine (10 mg/kg) and the respective controls, although D3(-/-) mice exhibited a decreased immobility time as compared to vehicle-injected controls. In contrast to WT animals, when treated with 1 mg/kg sertraline and the 4 mg/kg dose of every SSRI D3(-/-) mice exhibited a decreased immobility time in FST in comparison to vehicle-injected controls. Furthermore, 16 mg/kg doses of citalopram, paroxetine or sertraline induced a greater reduction of immobility time in D3(-/-) mice than in WT-treated animals as compared to their respective controls. These data suggest that D3(-/-) mice, as being more resistant to stressful procedure than WT littermates, are more sensitive to antidepressants in FST paradigm than the former. Although the present data do not allow any conclusion on the neurochemical base of this difference, it might be possible that the greater sensitivity to antidepressants depends on a higher DA levels in mesolimbic pathways following the lack of D3Rs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804207     DOI: 10.1016/j.euroneuro.2007.07.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  14 in total

1.  The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice.

Authors:  Wei-Li Chang; Mark A Geyer; Mahalah R Buell; Martin Weber; Neal R Swerdlow
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

2.  Unaltered D1, D2, D4, and D5 dopamine receptor mRNA expression and distribution in the spinal cord of the D3 receptor knockout mouse.

Authors:  Hong Zhu; Stefan Clemens; Michael Sawchuk; Shawn Hochman
Journal:  J Comp Physiol A Neuroethol Sens Neural Behav Physiol       Date:  2008-09-17       Impact factor: 1.836

3.  Short-Term Sleep Disturbance-Induced Stress Does not Affect Basal Pain Perception, but Does Delay Postsurgical Pain Recovery.

Authors:  Po-Kai Wang; Jing Cao; Hongzhen Wang; Lingli Liang; Jun Zhang; Brianna Marie Lutz; Kun-Ruey Shieh; Alex Bekker; Yuan-Xiang Tao
Journal:  J Pain       Date:  2015-09-03       Impact factor: 5.820

Review 4.  A new nosology of psychosis and the pharmacological basis of affective and negative symptom dimensions in schizophrenia.

Authors:  Costa Vakalopoulos
Journal:  Ment Illn       Date:  2010-05-06

5.  Short-term pre- and post-operative stress prolongs incision-induced pain hypersensitivity without changing basal pain perception.

Authors:  Jing Cao; Po-Kai Wang; Vinod Tiwari; Lingli Liang; Brianna Marie Lutz; Kun-Ruey Shieh; Wei-Dong Zang; Andrew G Kaufman; Alex Bekker; Xiao-Qun Gao; Yuan-Xiang Tao
Journal:  Mol Pain       Date:  2015-12-02       Impact factor: 3.395

6.  Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.

Authors:  Vanja Duric; Mounira Banasr; Tina Franklin; Ashley Lepack; Nika Adham; Béla Kiss; István Gyertyán; Ronald S Duman
Journal:  Int J Neuropsychopharmacol       Date:  2017-10-01       Impact factor: 5.176

Review 7.  Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?

Authors:  Gustavo A Angarita; Hasti Hadizadeh; Ignacio Cerdena; Marc N Potenza
Journal:  Expert Opin Pharmacother       Date:  2021-06-23       Impact factor: 4.103

8.  Dopamine D3 Receptor Mediates Preadolescent Stress-Induced Adult Psychiatric Disorders.

Authors:  Joon H Seo; Eldo V Kuzhikandathil
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

9.  Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).

Authors:  Tadakatsu Nakamura; Tomoko Kubota; Atsushi Iwakaji; Masayoshi Imada; Margit Kapás; Yasunori Morio
Journal:  Drug Des Devel Ther       Date:  2016-01-14       Impact factor: 4.162

10.  Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment`.

Authors:  Mariusz Papp; Piotr Gruca; Magdalena Lason-Tyburkiewicz; Ewa Litwa; Monika Niemczyk; Katarzyna Tota-Glowczyk; Paul Willner
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.